Earnings Recaps

Browse reported earnings of the most popular stocks

Apr 2, 2026 Apr 1, 2026 Mar 31, 2026 Mar 30, 2026 Mar 26, 2026 Mar 25, 2026 Mar 20, 2026 Mar 19, 2026 Mar 18, 2026 Mar 17, 2026 Mar 16, 2026 Mar 13, 2026 Mar 12, 2026 Mar 11, 2026 Mar 9, 2026 Mar 7, 2026 Mar 6, 2026 Mar 5, 2026 Mar 4, 2026 Mar 3, 2026 Mar 2, 2026 Feb 28, 2026 Feb 27, 2026 Feb 26, 2026 Feb 25, 2026 Feb 24, 2026 Feb 23, 2026 Feb 21, 2026 Feb 20, 2026 Feb 19, 2026 Feb 18, 2026 Feb 17, 2026 Feb 14, 2026 Feb 13, 2026 Feb 12, 2026 Feb 11, 2026 Feb 10, 2026 Feb 9, 2026 Feb 7, 2026 Feb 6, 2026 Feb 5, 2026 Feb 4, 2026 Feb 3, 2026 Feb 2, 2026 Jan 31, 2026 Jan 30, 2026 Jan 29, 2026 Jan 28, 2026 Jan 27, 2026 Jan 26, 2026 Jan 23, 2026 Jan 22, 2026 Jan 21, 2026 Jan 20, 2026 Jan 17, 2026 Jan 16, 2026 Jan 15, 2026 Jan 14, 2026 Jan 9, 2026 Jan 8, 2026 Jan 7, 2026 Jan 6, 2026 Dec 19, 2025 Dec 18, 2025 Dec 17, 2025 Dec 12, 2025 Dec 11, 2025 Dec 10, 2025 Dec 9, 2025 Dec 6, 2025 Dec 5, 2025 Dec 4, 2025 Dec 3, 2025 Dec 2, 2025 Dec 1, 2025 Nov 27, 2025 Nov 26, 2025 Nov 25, 2025 Nov 24, 2025 Nov 23, 2025 Nov 21, 2025 Nov 20, 2025 Nov 19, 2025 Nov 18, 2025 Nov 17, 2025 Nov 15, 2025 Nov 14, 2025 Nov 13, 2025 Nov 12, 2025 Nov 11, 2025 Nov 10, 2025 Nov 9, 2025 Nov 8, 2025 Nov 7, 2025 Nov 6, 2025 Nov 5, 2025 Nov 4, 2025 Nov 1, 2025 Oct 31, 2025 Oct 30, 2025 Oct 29, 2025 Oct 28, 2025 Oct 27, 2025 Oct 25, 2025 Oct 24, 2025 Oct 23, 2025 Oct 22, 2025 Oct 21, 2025 Oct 17, 2025 Oct 16, 2025 Oct 15, 2025 Oct 14, 2025 Oct 9, 2025 Oct 8, 2025 Oct 7, 2025 Sep 25, 2025 Sep 23, 2025 Sep 17, 2025 Sep 16, 2025 Sep 11, 2025 Sep 10, 2025 Sep 9, 2025 Sep 5, 2025 Sep 4, 2025 Sep 3, 2025 Sep 2, 2025 Sep 1, 2025 Aug 28, 2025 Aug 26, 2025 Aug 25, 2025 Aug 22, 2025 Aug 21, 2025 Aug 20, 2025 Aug 19, 2025 Aug 18, 2025 Aug 15, 2025 Aug 14, 2025 Aug 13, 2025 Aug 12, 2025 Aug 11, 2025 Aug 9, 2025 Aug 8, 2025 Aug 2, 2025 Aug 1, 2025 Jul 30, 2025 Jul 29, 2025 Jul 25, 2025
10 companies Today

AngioDynamics, Inc.

ANGO Q3 2026
Reported: 2026-04-02

AngioDynamics delivered another strong quarter, demonstrating sustained top-line growth and expanding profitability driven by robust performance in Med Tech and thrombectomy portfolios. The company continues to execute on strategic priorities, raising full-year guidance for the third consecutive quarter.

Key takeaways
  • Med Tech segment, led by Auryon, achieved 19th consecutive quarter of double-digit YoY growth, supported by international expansion post-CE Mark.
  • Thrombectomy portfolio (AlphaVac and AngioVac) grew approximately 18% YoY, with AlphaVac showing record sequential revenue increase and positive clinical adoption.
  • NanoKnife saw notable growth in disposables and capital, with expanded European indications and a favorable CMS CPT 1 code rollout bolstering market access.
  • The company reaffirmed its strategic focus on large, high-margin markets amid macro uncertainties, leveraging innovation and clinical milestones.
  • Full-year revenue and EBITDA guidance were raised for the third straight quarter, reflecting confidence in continued profitable growth.

Acuity Brands, Inc.

AYI Q2 2026
Reported: 2026-04-02

Acuity demonstrated robust Q2 fiscal 2026 growth with expanded operating margins and solid cash flow, despite a soft lighting environment and cautious near-term outlook.

Key takeaways
  • Net sales increased, and adjusted operating profit and margins grew, reflecting effective strategic execution and cost management.
  • The company actively aligns its cost base, including targeted labor reductions, to navigate a subdued lighting market while serving key verticals.
  • Recognition highlights include multiple industry awards for product innovation and strategic solutions in both lighting and controls segments.
  • Acuity’s growth strategy focuses on expanding into new verticals, market share gains, and product vitality, supported by recent acquisitions and product launches.
  • Full-year lighting sales are now expected to be flat to down low single digits, with continued emphasis on technology-driven productivity and long-term margin expansion.

Conagra Brands, Inc.

CAG Q3 2026
Reported: 2026-04-02

Conagra reports strong Q3 results driven by volume recovery and strategic pricing, with a focus on agility amid inflation uncertainties.

Key takeaways
  • Revenue growth fueled by increased volumes in frozen and snacks categories, despite some margin compression.
  • Approximately 60% material cost coverage in Q1 FY27, with strategic hedges in steel, freight, and crop ingredients.
  • Flexible approach to inflation: leveraging pricing elasticity in select categories while prioritizing volume momentum.
  • Portfolio resilience evident through superior responsiveness compared to peers, supported by innovation and value-driven offerings.
  • Management emphasizes agility to adapt to inflation trends, aiming to sustain profitable growth regardless of macroeconomic shifts.

Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector
Loading...